DOSE INTENSE MOPP FOR PATIENT WITH POOR PROGNOSIS HODGKINS DISEASE

“该协议旨在处理 最有可能接受治疗的霍奇金氏病患者 失败了。根据先前对晚期霍奇金氏病的研究，我们 已确定IIIB、IVB、IVA(骨髓)和 巨大纵隔霍奇金病的反应性较低 利率和存活率。为了提高MOPP的疗效 在这组患者的治疗中，所有药物的剂量强度都有 并给予GM-CSF治疗以改善重症 增加药物剂量的骨髓毒性作用。到目前为止，24人中有22人 可评估的患者已达到完全缓解。四名病人 已经故态复萌。一名诱导失败的患者自那以后 接受了异基因骨髓移植，并实现了 完整的回应。另一例诱导失败患者接受了ABMT， 获得CR，但两个月后复发，死于 进行性疾病。四名患者复发：一名患者为第二名 ABMT后，短时间的CR后复发。 另外两人目前正在接受治疗。其中23个 24名可评估的患者还活着：21名无病，2名 霍奇金氏病。没有观察到意外的毒性 通过这种治疗。这项研究接近应计项目，并有后续行动。 继续对未复发的患者进行治疗。

"This protocol was designed to treat the subset of Hodgkin's disease patients who are at highest risk for treatment failure. From the previous study of advanced Hodgkin's disease, we have identified patients with Stage IIIB, IVB, IVA (marrow) and massive mediastinal Hodgkin's disease as having lower response rates and survival. In order to improve the efficacy of MOPP therapy in this group of patients, the dose-intensity of all drugs has been increased and GM-CSF is given to ameliorate the severe myelotoxic effects of the increased drug doses. To date, 22 of 24 evaluable patients have achieved a complete response. Four patients have relapsed. One patient who was an induction failure has since undergone an allogeneic bone marrow transplant and achieved a complete response. The other induction failure underwent ABMT, achieved a CR, but relapsed after two months and died with progressive disease. Four patients have relapsed: one is in second CR following ABMT, one has relapsed following a short CR after ABMT; two others are currently receiving therapy. Twenty-three of 24 evaluable patients are alive: 21 free of disease, two with Hodgkin's disease. No unexpected toxicities have been observed with this treatment. This study is closed to accrual with follow-up continuing on non-relapsed patients."